Abstract: Described are compositions and methods relating to a coated granule comprising a core coated with cross-linkable polymer, where the cross-linkable polymer is applied using a feed suspension that includes an acid-neutralized volatile base and a calcium salt insoluble at the pH of the neutralized feed suspension. Volatilization of the base decreases the pH of the feed suspension, thereby solubilizing the calcium salt, and inducing in situ ion-mediated cross-linking of the cross-linkable polymer.

Abstract: An industrially scalable microcapsule, fiber or film forming process and formulations suitable for use in conventional spray drying systems are provided. The one-step spray drying process utilizes formulations of a first ionic polymer, a second ionic polymer with an isoelectric point (pI2) or acid dissociation constant (pKa2) that is greater than the isoelectric point (pI1) or acid dissociation constant (pKa1) of the first ionic polymer and a volatile base or volatile acid. Volatilization of the volatile base or acid of the spray formulation changes the pH of the solution and changes the charge of the second ionic polymer initiating electrostatic interactions with the first ionic polymer through complex coacervation. Microcapsules formed by the complex coacervation process can stabilize bioactive components as well as control the release of the bioactive components for a variety of applications.

Abstract: Systems and methods are provided for microencapsulating oxygen sensitive cargo such as polyunsaturated fatty acids and other oils by spray drying with an in situ internal gelation mechanism achieving cross-linking of polymers during the process, which is well-suited for industrial scale-up. Spray drying formulations of a mixture of an immiscible hydrophobic cargo and an emulsifier of a hydrophobically modified hydrophilic polymer with a suspension of a multivalent ion cross-linkable polymer, at least one acid, at least one volatile base and at least one salt of a multivalent ion can be adapted to provide control over particle size, degree of crosslinking, enteric release of cargo and shelf life. The methods produce microcapsules that enhance the shelf life of lipophilic bioactives while providing a mechanism of gastrointestinal delivery.

Abstract: Microencapsulation methods are provided using encapsulant, fiber or film forming compositions of a cross-linkable anionic polymer, a multivalent cation salt, a chelating agent, and a volatile base. During the formation of this composition, the generally acidic chelating agent is titrated with a volatile base to an elevated pH to improve ion-binding capability. Multivalent cations are sequestered in cation-chelate complexes. Cross-linkable polymers in this solution will remain freely dissolved until some disruption of equilibrium induces the release of the free multivalent cations from the cation-chelate complex. Vaporization of the volatile base drops the pH of the solution causing the cation-chelate complexes to dissociate and liberate multivalent cations that associate with the anionic polymer to form a cross-linked matrix. During spray-drying, the formation of a wet particle, polymer cross-linking, and particle drying occur nearly simultaneously.

Abstract: An industrially scalable microcapsule, fiber or film forming process and formulations suitable for use in conventional spray drying systems are provided. The one-step spray drying process utilizes formulations of a first ionic polymer, a second ionic polymer with an isoelectric point (pI2) or acid dissociation constant (pKa2) that is greater than the isoelectric point (pI1) or acid dissociation constant (pKa1) of the first ionic polymer and a volatile base or volatile acid. Volatilization of the volatile base or acid of the spray formulation changes the pH of the solution and changes the charge of the second ionic polymer initiating electrostatic interactions with the first ionic polymer through complex coacervation. Microcapsules formed by the complex coacervation process can stabilize bioactive components as well as control the release of the bioactive components for a variety of applications.

Abstract: Microencapsulation of bioactive and chemical cargo in a stable, cross-linked polymer matrix is presented that results in small particle sizes and is easily scaled-up for industrial applications. A formulation of a salt of an acid soluble multivalent ion, an acid neutralized with a volatile base and one or more monomers that cross-link in the presence of multivalent ions is atomized into droplets. Cross-linking is achieved upon atomization where the volatile base is vaporized resulting in a reduction of the pH of the formulation and the temporal release of multivalent ions from the salt that cross-link the monomers forming a capsule. The incorporation of additional polymers or hydrophobic compounds in the formulation allows control of hydration properties of the particles to control the release of the encapsulated compounds. The operational parameters can also be controlled to affect capsule properties such as particle-size and particle-size distribution.

Abstract: Microencapsulation of bioactive and chemical cargo in a stable, cross-linked polymer matrix is presented that results in small particle sizes and is easily scaled-up for industrial applications. A formulation of a salt of an acid soluble multivalent ion, an acid neutralized with a volatile base and one or more monomers that cross-link in the presence of multivalent ions is atomized into droplets. Cross-linking is achieved upon atomization where the volatile base is vaporized resulting in a reduction of the pH of the formulation and the temporal release of multivalent ions from the salt that cross-link the monomers forming a capsule. The incorporation of additional polymers or hydrophobic compounds in the formulation allows control of hydration properties of the particles to control the release of the encapsulated compounds. The operational parameters can also be controlled to affect capsule properties such as particle-size and particle-size distribution.

Abstract: Microencapsulation of bioactive and chemical cargo in a stable, cross-linked polymer matrix is presented that results in small particle sizes and is easily scaled-up for industrial applications. A formulation of a salt of an acid soluble multivalent ion, an acid neutralized with a volatile base and one or more monomers that cross-link in the presence of multivalent ions is atomized into droplets. Cross-linking is achieved upon atomization where the volatile base is vaporized resulting in a reduction of the pH of the formulation and the temporal release of multivalent ions from the salt that cross-link the monomers forming a capsule. The incorporation of additional polymers or hydrophobic compounds in the formulation allows control of hydration properties of the particles to control the release of the encapsulated compounds. The operational parameters can also be controlled to affect capsule properties such as particle-size and particle-size distribution.

Abstract: The present disclosure is generally related a method for the liquefaction of high-solids biomass substrates. Particularly, biomass can be added to a reactor until a pressure drop, measured inline, reaches the maximum system limitations. A commercial enzyme mixture (specific for the particular type of biomass to be processed) may then be added to the biomass, forming a slurry. The pressure may be continuously monitored and when the pressure drop reaches a steady state (which can be determined by little or no change in pressure drop for several minutes), more biomass may then be added until the high pressure limit of the pump system is reached again. The method can be repeated until the desired quantity of biomass is processed.

Abstract: Microencapsulation of bioactive and chemical cargo in a stable, cross-linked polymer matrix is presented that results in small particle sizes and is easily scaled-up for industrial applications. A formulation of a salt of an acid soluble multivalent ion, an acid neutralized with a volatile base and one or more monomers that cross-link in the presence of multivalent ions is atomized into droplets. Cross-linking is achieved upon atomization where the volatile base is vaporized resulting in a reduction of the pH of the formulation and the temporal release of multivalent ions from the salt that cross-link the monomers forming a capsule. The incorporation of additional polymers or hydrophobic compounds in the formulation allows control of hydration properties of the particles to control the release of the encapsulated compounds. The operational parameters can also be controlled to affect capsule properties such as particle-size and particle-size distribution.

Abstract: Provided herein is an isolated Cel7A polypeptide comprising mutations in the catalytic domain of the polypeptide relative to the catalytic domain of a wild type Cel7A polypeptide, wherein the mutations reduce N-linked glycosylation of the isolated polypeptide relative to the wild type polypeptide. Also provided herein is an isolated Cel7A polypeptide comprising increased O-linked glycosylation of the linker domain relative to a linker domain of a wild type Cel7A polypeptide. The increased O-linked glycosylation is a result of the addition of and/or substitution of one or more serine and/or threonine residues to the linker domain relative to the linker domain of the wild type polypeptide. In some embodiments, the isolated Cel7A polypeptide comprising mutations in the catalytic domain of the polypeptide relative to the catalytic domain of a wild type Cel7A polypeptide further comprises increased O-linked glycosylation of the linker domain relative to a linker domain of a wild type Cel7A polypeptide.

Abstract: Provided herein is an isolated Cel7A polypeptide comprising mutations in the catalytic domain of the polypeptide relative to the catalytic domain of a wild type Cel7A polypeptide, wherein the mutations reduce N-linked glycosylation of the isolated polypeptide relative to the wild type polypeptide. Also provided herein is an isolated Cel7A polypeptide comprising increased O-linked glycosylation of the linker domain relative to a linker domain of a wild type Cel7A polypeptide. The increased O-linked glycosylation is a result of the addition of and/or substitution of one or more serine and/or threonine residues to the linker domain relative to the linker domain of the wild type polypeptide. In some embodiments, the isolated Cel7A polypeptide comprising mutations in the catalytic domain of the polypeptide relative to the catalytic domain of a wild type Cel7A polypeptide further comprises increased O-linked glycosylation of the linker domain relative to a linker domain of a wild type Cel7A polypeptide.